---
title: "Biogen Inc. Stock Outperforms Competitors On Strong Trading Day"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296652649.md"
description: "Biogen Inc. (BIIB) shares rose 1.13% to $216.78 on Friday, outperforming the broader market as the S&P 500 and Dow Jones gained. The stock closed 2.42% below its 52-week high of $222.15. While competitors like Johnson & Johnson, Pfizer, and AbbVie also saw gains, Biogen's trading volume was significantly lower than its 50-day average."
datetime: "2026-08-21T20:57:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296652649.md)
  - [en](https://longbridge.com/en/news/296652649.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296652649.md)
generator: "portal-rs"
---

# Biogen Inc. Stock Outperforms Competitors On Strong Trading Day

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Biogen Inc. (BIIB) advanced 1.13% to $216.78 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 0.43% to 7,674.37 and the Dow Jones Industrial Average rising 0.98% to 53,277.01.

Biogen Inc. closed 2.42% below its 52-week high of $222.15, which the company achieved on August 19th.

The stock demonstrated a mixed performance when compared to some of its competitors Friday, as Johnson & Johnson (JNJ) rose 1.07% to $270.24, Pfizer Inc. (PFE) rose 1.01% to $28.07, and AbbVie Inc. (ABBV) rose 1.20% to $264.96.

Trading volume (722,346) remained 497,941 below its 50-day average volume of 1.2 M.

Data source: Dow Jones Market Data, FactSet. Data compiled August 21, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

08-21-26 1657ET

### Related Stocks

- [BIIB.US](https://longbridge.com/en/quote/BIIB.US.md)
- [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md)
- [.DJI.US](https://longbridge.com/en/quote/.DJI.US.md)
- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)
- [PFE.US](https://longbridge.com/en/quote/PFE.US.md)
- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [Amundi Purchases 726,004 Shares of Biogen Inc. $BIIB](https://longbridge.com/en/news/298275504.md)
- [Learn Why The Bull Case For Biogen Stock Could Change Following Canada Reimbursement Backing](https://longbridge.com/en/news/298400767.md)
- [Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI(R) (lecanemab) for Early Alzheimer's Disease](https://longbridge.com/en/news/298340520.md)
- [Biogen And Eisai Announce China Approval For Subcutaneous LEQEMBI To Treat Early Alzheimer's Disease](https://longbridge.com/en/news/297867394.md)
- [Is Biohaven (BHVN) Priced At A Premium After Its 36% Rise?](https://longbridge.com/en/news/298501231.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**